Jacklyn Gideon, MSN, AGPCNP-BC, an Advanced Practice Nurse at the University of Chicago, talks about R2 dosing and the 12-cycle fixed-duration treatment of follicular lymphoma in the Phase III AUGMENT trial.
Clinical Trial Data
In the pivotal Phase III AUGMENT trial, R2 was studied in a broad range of patients with previously treated FL or MZL. R2 showed a median progression-free survival of 39.4 months compared to 14.1 months with rituximab alone-that’s more than two times longer PFS.
Mechanism of Action
Dr. Joseph Tuscano, Professor of Medicine at UC Davis, explains how this immunotherapy combination has been shown to increase immune-mediated killing via ADCC and increase direct tumor apoptosis in FL and MZL cells in vitro.
Learn more about treating patients with follicular lymphoma and how REVLIMID + rituximab has been shown to increase immune-mediated killing via ADCC and increase direct tumor apoptosis in FL and MZL cells in vitro.
Lenalidomide (REVLIMID) + rituximab is a preferred treatment option (Category 2A) recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for second-line and subsequent therapy for patients with Grade 1-2 follicular lymphoma.3*